Bausch Health (BHC)
(Delayed Data from NYSE)
$7.95 USD
-0.15 (-1.85%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Company Summary
Based in British Columbia, Canada, Bausch Health Companies Inc. develops, manufactures and markets a wide range of branded, generic and branded generic pharmaceuticals as well as over-the-counter (OTC) products in the therapeutic areas of gastroenterology (GI), hepatology, neurology, dermatology and aesthetic medical devices. The company also markets branded and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health through its majority stake in Bausch + Lomb Corporation. In May 2022, Bausch launched the initial public offering (IPO) for its eye health business, Bausch + Lomb, which ...
Company Summary
Based in British Columbia, Canada, Bausch Health Companies Inc. develops, manufactures and markets a wide range of branded, generic and branded generic pharmaceuticals as well as over-the-counter (OTC) products in the therapeutic areas of gastroenterology (GI), hepatology, neurology, dermatology and aesthetic medical devices. The company also markets branded and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health through its majority stake in Bausch + Lomb Corporation. In May 2022, Bausch launched the initial public offering (IPO) for its eye health business, Bausch + Lomb, which subsequently began trading under the ticker "BLCO" on May 6, 2022. Bausch Health owns an 88% majority stake in Bausch + Lomb. The completion of this separation is contingent on the achievement of targeted debt leverage ratios and the receipt of other necessary approvals.
However, Solta Medical's IPO has been suspended due to challenging market conditions and other factors. Solta is Bausch’s medical aesthetics unit with innovative and effective skin rejuvenation and body contouring solutions, including the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. Bausch will revisit alternative paths for Solta in the future. The company will now focus on Bausch Pharma and Solta businesses.
The Salix segment consists of GI products in the United States. Sales of the Xifaxan product line represented approximately 80% of the Salix segment’s revenues. The International segment consists of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceuticals and OTC products. The Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. The Diversified Products segment consists of sales (in the United States) of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, dermatological products and dentistry products.
The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care and surgical and pharmaceutical products.
Revenues in 2023 came in at $8.76 billion, up 8% from 2022.
General Information
Bausch Health Cos Inc
2150 ST. ELZEAR BLVD. WEST
LAVAL, A8 H7L 4A8
Phone: 514-744-6792
Fax: 514-744-6272
Web: http://www.bauschhealth.com
Email: ir@bauschhealth.com
Industry | Medical - Generic Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Earnings Date | 10/30/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.05 |
Current Year EPS Consensus Estimate | 3.61 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 10/30/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 8.10 |
52 Week High | 11.46 |
52 Week Low | 3.96 |
Beta | 0.77 |
20 Day Moving Average | 2,325,514.50 |
Target Price Consensus | 7.79 |
4 Week | 28.57 |
12 Week | 9.76 |
YTD | 1.00 |
4 Week | 24.47 |
12 Week | 5.28 |
YTD | -16.66 |
Shares Outstanding (millions) | 361.33 |
Market Capitalization (millions) | 2,926.78 |
Short Ratio | 1.00 |
Last Split Date | 10/16/2000 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 2.24 |
Trailing 12 Months | 2.21 |
PEG Ratio | NA |
vs. Previous Year | 9.88% |
vs. Previous Quarter | 50.85% |
vs. Previous Year | 10.89% |
vs. Previous Quarter | 11.61% |
Price/Book | NA |
Price/Cash Flow | 1.12 |
Price / Sales | 0.32 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -742.06 |
3/31/24 | -2,370.91 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 4.94 |
3/31/24 | 4.88 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.19 |
3/31/24 | 1.23 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.82 |
3/31/24 | 0.85 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 14.48 |
3/31/24 | 14.54 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -5.12 |
3/31/24 | -5.07 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -3.85 |
3/31/24 | -3.60 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -0.63 |
3/31/24 | -0.47 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 1.77 |
3/31/24 | 1.84 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |